Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer
- Resource Type
- Article
- Authors
- Burrows, Natalie; Maxwell, Patrick H.
- Source
- Nature Reviews Urology; 20240101, Issue: Preprints p1-2, 2p
- Subject
- Language
- ISSN
- 17594812; 17594820
A new phase I clinical trial has demonstrated that belzutifan provides a route to sustained inhibition of hypoxia-inducible factor 2α in humans that is well tolerated and could be useful in the treatment of advanced clear cell kidney cancer.